Anti-angiogenic therapy, such as antibodies to vascular endothelial growth factors (VEGF), has shown efficacy clinically in treating wet AMD, the leading blinding disease in the elderly (Brown et al., 2006; Rosenfeld et al., 2006; Zampros et al., 2012; Hurwitz et al., 2004). The gene discussed is VEGFA; the disease is wet macular degeneration.